Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Abatacept plus

Phase 3

MMassachusetts General Hospital

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Myocarditis AcuteRecruiting

Myocarditis AcutePhase 3

Recruiting

Timeline

Expected Milestones

Q4 2029

Phase 3Recruiting

Myocarditis Acute

NCT05335928

Clinical

Trials by Indication[1]

Myocarditis Acute1 trial

AbatacepT foR ImmUne Checkpoint Inhibitor Associated Myocarditis (ATRIUM): A Phase 3, Investigator-Initiated, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept in ICI Myocarditis

Recruiting·MMassachusetts General Hospital·Phase 3·NCT05335928·390 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Abatacept plus. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Abatacept plus. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Massachusetts General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: MMassachusetts General Hospital

Related News